摘要
目的:研究含CDgly ES双功能融合基因的重组腺病毒(rAdCDglyES)对肿瘤的直接、间接杀伤作用及其对放射的增敏作用。方法:建立MA737乳腺癌津白Ⅱ号小鼠荷瘤模型,按分组要求给予不同处理,设定多个观察指标对各组结果进行比较。结果:按分组要求处理后第25天,第1组瘤体达2.5cm×2.3cm;第6组肿瘤为1.4cm×1.2cm。第6组的中位生存期明显长于其余各组,P<0.01。第1组的凋亡指数较低,平均为2.61‰,而第6组的凋亡指数较高,平均为6.84‰,两组比较差异有统计学意义。第1组的微血管密度(MVD)值较高,为145.81,第6组的MVD值较低,为121.23,P<0.05。结论:含双功能融合基因的重组腺病毒在局部对肿瘤细胞具有直接杀伤作用,亦可抑制肿瘤新生血管的形成,对肿瘤细胞显示间接抑制、杀伤作用;显示该重组腺病毒能够和射线发生协同作用,增加局部放射对肿瘤的抑制作用。
Objective： To determine if the recombinant fusion gene rAdCDglyES has a significant direct or indirect antitumor effect in vivo in order to enhance the effects of radiochemy. Methods： Seventy-two Jinbai-Ⅱ mice were divided into 6 groups at random and human MA737 breast cancer cells were implanted. Each group received a different treatment： Several parameters were observed to compare the results of the treatments. Results： On the 25th day after treatment, the size of the tumors in group 1 reached 2.5cm×2.3cm, and the size of the tumors in group 6 reached 1.4cm×1.2cm. The median survival in group 6 was conspicuously longer compared to the other groups （P〈0.01）. The apoptotic index in group 1 was low, with an average of 2.61%, whereas that in group 6 was rather high, averaging 6.84%. There was a statistically significant difference between the two. The microvessel density （MVD） in group 1 was high, reaching 145.81, and that in group 6 was low, with 121.23 （P〈0.05）. Conclusion： The results indicate that the rAdCDglyES system has the ability to inhibit tumor cells directly and indirectly in vivo. The combined treatment is more effective than other therapies alone.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第3期168-170,共3页
Chinese Journal of Clinical Oncology
基金
天津市科委基金资助(编号:013615811)
关键词
内皮抑素
重组腺病毒
基因治疗
肿瘤
CD gene ES gene Recombinant adenovirus Gene therapy Tumor
